Jayson Rieger

Managing Partner

Jayson supports new investment evaluation, deal sourcing and provides technical and business support for portfolio companies. Jayson has over 20 years experience in cross-functional scientific and business leadership roles spanning business development, research operations, drug discovery and product development in the life sciences industry. He is an entrepreneurial-minded scientist and business leader with material involvement in multiple successful investor exits. Currently he supports the existing portfolio companies in the capacity of CEO of Xalud Therapeutics, CDO of Baxis Pharmaceuticals and COO of Vetana.  He also serves on the Board of Directors of Xalud Therapeutics, Baxis Pharmaceuticals, Vetana and Lytix Biopharma.  Prior to joining PBM he served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, a synthetic biology company that had an IPO in August 2013 (NYSE: XON). Jayson has also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc. (NSDQ: CLDA), prior to its acquisition by Forest Labs in 2011. Jayson has also held the role of Vice President of Lead Development at Adenosine Therapeutics, LLC, prior to its acquisition by Clinical Data in 2008.

Jayson has delivered a number of invited lectures at universities and scientific conferences and has served as a key team member in multiple development programs ranging from discovery stage research to Phase III clinical trials. He is the recipient of more than 10 federal grants, serving as both principal and co-investigator on efforts targeted towards evaluating adenosine receptor agents in a variety of disease indications. He is a co-inventor on more than 25 patents and has authorship on more than 25 peer-reviewed scientific publications.

Jayson obtained his Ph.D. from the University of Virginia in Chemistry, has an MBA from the Darden Business School and earned his B.A. from Rollins College.